UNICYCIVE THERAPEUTICS, INC. Employee Benefits and Share-based Compensation
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Employee Benefits and Share-based Compensation of $294.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2023-08-14
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-06-30 was $294.00K, a 104.17% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2023-03-31 was $144.00K, a 50.34% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2022-12-31 was $197.00K, a 14.72% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for the quarter ending 2022-09-30 was $266.00K, a 11.30% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for fiscal 2022 was $1.05M, a 8.39% increase from fiscal 2021.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for fiscal 2021 was $966.00K, a 316.38% increase from fiscal 2020.
- UNICYCIVE THERAPEUTICS, INC. employee benefits and share-based compensation for fiscal 2020 was $232.00K.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 3 month as first filed | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 6 month as first filed | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $294.00K 10-Q · filed 2023-08-14 | $584.00K 10-Q · filed 2023-08-14 | $635.00K derived: sum of 3 quarters · filed 2023-08-14 | $901.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2023-03-31 | $144.00K 10-Q · filed 2023-05-16 | $341.00K derived: sum of 2 quarters · filed 2023-05-16 | $607.00K derived: sum of 3 quarters · filed 2023-05-16 | $751.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $463.00K derived: sum of 2 quarters · filed 2023-03-31 | $607.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.05M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $266.00K 10-Q · filed 2022-11-14 | $410.00K derived: sum of 2 quarters · filed 2023-08-14 | $850.00K 10-Q · filed 2022-11-14 | $931.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-06-30 | $144.00K 10-Q · filed 2023-08-14 | $294.00K 10-Q · filed 2022-08-15 | $288.00K 10-Q · filed 2023-08-14 | $584.00K 10-Q · filed 2022-08-15 | $665.00K derived: sum of 3 quarters · filed 2023-08-14 | $904.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $290.00K 10-Q · filed 2023-05-16 | $521.00K derived: sum of 2 quarters · filed 2023-05-16 | $760.00K derived: sum of 3 quarters · filed 2023-05-16 | $1.05M derived: sum of 4 quarters · filed 2023-05-16 | ||
| 2021-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $470.00K derived: sum of 2 quarters · filed 2023-03-31 | $764.00K derived: sum of 3 quarters · filed 2023-03-31 | $966.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $239.00K 10-Q · filed 2022-11-14 | $533.00K derived: sum of 2 quarters · filed 2022-11-14 | $735.00K 10-Q · filed 2022-11-14 | $806.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $294.00K 10-Q · filed 2022-08-15 | $496.00K 10-Q · filed 2022-08-15 | $567.00K derived: sum of 3 quarters · filed 2022-08-15 | $638.00K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $202.00K 10-Q · filed 2022-05-12 | $273.00K derived: sum of 2 quarters · filed 2022-05-12 | $344.00K derived: sum of 3 quarters · filed 2022-05-12 | $404.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $142.00K derived: sum of 2 quarters · filed 2022-03-31 | $202.00K derived: sum of 3 quarters · filed 2022-03-31 | $232.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $71.00K 10-Q · filed 2021-11-12 | $131.00K derived: sum of 2 quarters · filed 2021-11-12 | $161.00K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $60.00K 10-Q · filed 2021-08-16 | $91.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |